Compare GABC & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | NKTR |
|---|---|---|
| Founded | 1910 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 1995 | 1996 |
| Metric | GABC | NKTR |
|---|---|---|
| Price | $51.06 | $73.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $47.67 | ★ $146.67 |
| AVG Volume (30 Days) | 152.3K | ★ 676.7K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 8.13 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $487,401,000.00 | $307,711,000.00 |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $58.00 | ★ N/A |
| Revenue Growth | 37.80 | ★ 86.00 |
| 52 Week Low | $37.19 | $22.01 |
| 52 Week High | $52.23 | $109.00 |
| Indicator | GABC | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.